Antiplatelet therapy in the acute phase of ischemic stroke

doi:10.3969/j.issn.1004-583X.2026.06.001

Abstract

Abstract:

The acute phase of ischemic stroke is a high-risk period for neurological deterioration and early recurrence. The primary goal of antiplatelet therapy is to inhibit platelet activation as early as possible, thereby reducing the risk of ischemic events while strictly controlling bleeding complications. In patients with non-cardioembolic acute ischemic stroke, antiplatelet therapy should be initiated as early as possible after intracranial hemorrhage has been excluded, in order to reduce the risks of early stroke progression, recurrence, and other vascular events. This article systematically reviews the development of acute-phase antiplatelet therapy over the past 30 years and the latest research advances, with the aim of providing a theoretical basis and reference for the precise selection of antiplatelet agents and the development of individualized treatment strategies in clinical practice.

Key words: ischemic stroke, acute phase, antiplatelet therapy

CLC Number:

R743.3

Ouyang Qian, Zhao Ying, Meng Heng, Xu Anding. Antiplatelet therapy in the acute phase of ischemic stroke[J]. Clinical Focus, 2026, 41(6): 485-492.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2026.06.001

https://www.lchc.cn/EN/Y2026/V41/I6/485

References 38

[1]	国家卫生健康委加强脑卒中防治工作减少百万新发残疾工程专家委员会, 吉训明. 《2024年中国脑卒中防治报告》概要[J]. 首都医科大学学报, 2025, 46(06):947-960. doi:10.3969/j.issn.1006-7795.2025.06.001.
[2]	Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association[J]. Stroke, 2021, 52(7):e364-e467. doi:10.1161/STR.0000000000000375.
[3]	CAST: randomised placebo-controlled trial of early aspirin use in 20, 000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group[J]. Lancet, 1997, 349(9066):1641-1649. doi: 10.1016/S0140-6736(97)04010-5 URL
[4]	The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke[J]. Lancet, 1997, 349(9065): 1569-1581. doi: 10.1016/S0140-6736(97)04011-7 URL
[5]	Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups[J]. Stroke, 2000, 31(6):1240-1249. doi:10.1161/01.str.31.6.1240. pmid: 10835439
[6]	中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性卒中诊治指南2023[J]. 中华神经科杂志, 2024, 57(6): 523-559. doi: 10.3760/cma.j.cn113694-20240410-00221.
[7]	Prabhakaran S, Gonzalez NR, Zachrison KS, et al. 2026 Guideline for the early management of patients with acute ischemic stroke: A guideline from the American Heart Association/American Stroke Association[J]. Stroke, 2026, 57(1):e1-e119.doi:10.1161/STR.0000000000000513.
[8]	Zhao Y, Yang W, Tan Z, et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): Results from a prospective double-blind randomised clinical trial[J]. Stroke Vasc Neurol, 2017, 2(3):118-123. doi:10.1136/svn-2017-000072. pmid: 28989802
[9]	Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack[J]. N Engl J Med, 2016, 375(1):35-43. doi:10.1056/NEJMoa1603060.
[10]	Zeinhom MG, Elbassiouny A, Mohamed AM, et al. Ticagrelor versus clopidogrel in acute large-vessel ischemic stroke: A randomized controlled single-blinded trial[J]. CNS Drugs, 2024, 38(5):387-398. doi:10.1007/s40263-024-01080-5. pmid: 38619649
[11]	Han B, Ma T, Liu Z, et al. Efficacy and safety of tirofiban in clinical patients with acute ischemic stroke[J]. Front Neurol, 2022, 12:785836. doi:10.3389/fneur.2021.785836.
[12]	Yu Y, Zheng Y, Dong X, et al. Efficacy and safety of tirofiban in patients with acute ischemic stroke without large-vessel occlusion and not receiving intravenous thrombolysis: A randomized controlled open-label trial[J]. J Neurorestoratology, 2022, 10(4):1-7. doi: 10.1016/j.jnrt.2022.100026.
[13]	Zhao W, Li S, Li C, et al. Effects of tirofiban on neurological deterioration in patients with acute ischemic stroke[J]. JAMA Neurology, 2024, 81(6):594-602.doi: 10.1001/jamaneurol.2024.0868.
[14]	Wen Q, Zhao Y, Deng Y, et al. Tirofiban for preventing early neurological deterioration in acute ischemic stroke within 48 hours of onset: Evidence from a dual‐method analysis using propensity score matching and multivariable regression[J]. CNS Neurosci Ther, 2025, 31(12):e70718. doi: 10.1002/cns.70718.
[15]	Zi W, Song J, Kong W, et al. Tirofiban for stroke without large or medium-sized vessel occlusion[J]. N Engl J Med, 2023, 388(22): 2025-2036. doi: 10.1056/NEJMoa2214299.
[16]	Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med, 2013, 369(1): 11-19. doi: 10.1056/NEJMoa1215340.
[17]	Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA[J]. N Engl J Med, 2018, 379(3): 215-225. doi: 10.1056/NEJMoa1800410.
[18]	Johnston SC, Elm JJ, Easton JD, et al. Time course for benefit and risk of clopidogrel and aspirin after acute transient ischemic attack and minor ischemic stroke[J]. Circulation, 2019, 140(8): 658-664. doi: 10.1161/circulationaha.119.040713. pmid: 31238700
[19]	Pan Y, Elm J J, Li H, et al. Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack[J]. JAMA Neurol, 2019, 76(12):1466-1473.doi: 10.1001/jamaneurol.2019.2531.
[20]	Gao Y, Chen W, Pan Y, et al. Dual antiplatelet treatment up to 72 hours after ischemic stroke[J]. N Engl J Med, 2023, 389(26): 2413-2424. doi: 10.1056/NEJMoa2309137.
[21]	Chen HS, Cui Y, Wang XH, et al. Clopidogrel plus aspirin vs aspirin alone in patients with acute mild to moderate stroke[J]. JAMA Neurol, 2024, 81(5):450-460. doi: 10.1001/jamaneurol.2024.0146.
[22]	Dawson J, Merwick Á, Webb A, et al. European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA[J]. Eur Stroke J, 2021, 6(2): CLXXXVII-CXCI. doi: 10.1177/23969873211000877.
[23]	Wang Y, Zhao X, Lin J, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack[J]. JAMA, 2016, 316(1):70-78.doi: 10.1001/jama.2016.8662. pmid: 27348249
[24]	Wang Y, Chen W, Lin Y, et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: Open label, blinded endpoint, randomised controlled phase II trial[J]. BMJ, 2019, 365: 12211. doi: 10.1136/bmj.l2211.
[25]	Wang Y, Meng X, Wang A, et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA[J]. N Engl J Med, 2021, 385(27): 2520-2530. doi: 10.1056/NEJMoa2111749.
[26]	Lun R, Dhaliwal S, Zitikyte G, et al. Comparison of ticagrelor vs clopidogrel in addition to aspirin in patients with minor ischemic stroke and transient ischemic attack[J]. JAMA Neurology, 2022, 79(2): 141-148. doi: 10.1001/jamaneurol.2021.4514.
[27]	Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA[J]. N Engl J Med, 2020, 383(3): 207-217. doi: 10.1056/NEJMoa1916870.
[28]	Amarenco P, Denison H, Evans SR, et al. Ticagrelor added to aspirin in acute ischemic stroke or transient ischemic attack in prevention of disabling stroke[J]. JAMA Neurol, 2020, 78(2):1-9. doi: 10.1001/jamaneurol.2020.4396.
[29]	Amarenco P, Denison H, Evans SR, et al. Ticagrelor added to aspirin in acute nonsevere ischemic stroke or transient ischemic attack of atherosclerotic origin[J]. Stroke, 2020, 51(12): 3504-3513. doi: 10.1161/strokeaha.120.032239. pmid: 33198608
[30]	Bath PM, Woodhouse LJ, Appleton JP, et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): A randomised, open-label, phase 3 superiority trial[J]. Lancet, 2018, 391(10123): 850-859. doi: 10.1016/s0140-6736(17)32849-0. pmid: 29274727
[31]	Kim TJ, Lee JS, Yoon JS, et al. Multiple antiplatelet therapy in ischemic stroke already on antiplatelet agents based on the linked big data for stroke[J]. J Korean Med Sci, 2023, 38(38):e294. doi: 10.3346/jkms.2023.38.e294. pmid: 37750368
[32]	Zinkstok SM, Roos YB. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: A randomised controlled trial[J]. Lancet, 2012, 380(9843): 731-737. doi: 10.1016/s0140-6736(12)60949-0. pmid: 22748820
[33]	Tao C, Liu T, Cui T, et al. Early tirofiban infusion after intravenous thrombolysis for stroke[J]. N Engl J Med, 2025, 393(12): 1191-1201. doi: 10.1056/NEJMoa2503678.
[34]	Shuai J, Gong Z, Huang L, et al. Effect of intravenous tirofiban vs placebo before endovascular thrombectomy on functional outcomes in large vessel occlusion stroke[J]. JAMA, 2022, 328(6):543-553. doi: 10.1001/jama.2022.12584.
[35]	Sang H, Xie D, Tian Y, et al. Association of tirofiban with functional outcomes after thrombectomy in acute ischemic stroke due to intracranial atherosclerotic disease[J]. Neurology, 2023, 100(19): e1996-e2006. doi: 10.1212/wnl.0000000000207194.
[36]	Rong B, Guo Z, Gao L, et al. Association of tirofiban treatment with outcomes following endovascular therapy in cardioembolic stroke: Insights from the RESCUE BT randomized trial[J]. Eur J Med Res, 2023, 28(1):473.doi: 10.1186/s40001-023-01406-x.
[37]	Lin L, Liu F, Yi T, et al. Tirofiban on first-pass recanalization in acute stroke endovascular thrombectomy[J]. JAMA Network Open, 2025, 8(4):e255308.doi: 10.1001/jamanetworkopen.2025.5308.
[38]	中国卒中学会, 中国卒中学会神经介入分会, 中华预防医学会卒中预防与控制专业委员会介入学组. 替罗非班在动脉粥样硬化性脑血管疾病中的临床应用专家共识[J]. 中国卒中杂志, 2019, 14(10):1034-1044. doi:10.3969/j.issn.1673-5765.2019.10.013.